0001209191-23-010061.txt : 20230216
0001209191-23-010061.hdr.sgml : 20230216
20230216161826
ACCESSION NUMBER: 0001209191-23-010061
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230214
FILED AS OF DATE: 20230216
DATE AS OF CHANGE: 20230216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tatsis Ourania
CENTRAL INDEX KEY: 0001789815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23638732
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-14
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001789815
Tatsis Ourania
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Reg. & Quality Off.
Common Stock
2023-02-14
4
S
0
71
295.89
D
65694
D
Common Stock
2023-02-14
4
S
0
20
296.48
D
65674
D
Common Stock
2023-02-14
4
S
0
43
297.98
D
65631
D
Common Stock
2023-02-14
4
S
0
135
299.60
D
65496
D
Common Stock
2023-02-14
4
S
0
51
300.58
D
65445
D
Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.36 to $296.32).
Open market sales reported on this line occurred at a weighted average price of $297.98 (range $297.50 to $298.48).
Open market sales reported on this line occurred at a weighted average price of $299.60 (range $299.19 to $300.16).
Open market sales reported on this line occurred at a weighted average price of $300.58 (range $300.34 to $301.01).
/s/ Christiana Stevenson, Attorney-in-Fact
2023-02-16